Earnings summaries and quarterly performance for BIO-RAD LABORATORIES.
Executive leadership at BIO-RAD LABORATORIES.
Norman Schwartz
Detailed
Chief Executive Officer
CEO
Colleen Corey
Detailed
Executive Vice President, Global Human Resources
Courtney Enloe
Detailed
Executive Vice President, General Counsel and Secretary
Eva Engelhardt
Detailed
Executive Vice President and President, Clinical Diagnostics Group
James Barry
Detailed
Executive Vice President and President, Life Science Group
Jonathan DiVincenzo
Detailed
President and Chief Operating Officer
Rajat Mehta
Detailed
Executive Vice President, Global Commercial Operations
Roop Lakkaraju
Detailed
Executive Vice President, Chief Financial Officer
Sedat Evran
Detailed
Executive Vice President, Global Supply Chain
Board of directors at BIO-RAD LABORATORIES.
Research analysts who have asked questions during BIO-RAD LABORATORIES earnings calls.
Brandon Couillard
Wells Fargo & Company
4 questions for BIO
Also covers: A, AVTR, BRKR +10 more
Jack Meehan
Nephron Research LLC
4 questions for BIO
Also covers: A, AVTR, CARS +17 more
Tycho Peterson
Jefferies
3 questions for BIO
Also covers: A, AVTR, BLLN +22 more
Conor Noel McNamara
RBC Capital Markets
2 questions for BIO
Also covers: AVTR, HOLX, ILMN +6 more
Daniel Leonard
Stifel Financial Corp.
2 questions for BIO
Also covers: A, AVTR, CRL +15 more
Patrick Donnelly
Citi
2 questions for BIO
Also covers: A, AVTR, BRKR +21 more
Dan Leonard
UBS Group AG
1 question for BIO
Also covers: A, AVTR, DHR +9 more
David Carter
RBC Capital Markets
1 question for BIO
Matt Taylor
Jefferies & Company Inc.
1 question for BIO
Also covers: BAX, DXCM, ESTA +10 more
Recent press releases and 8-K filings for BIO.
BIO Reports Q3 2025 Financial Results and Reaffirms Full-Year Outlook
BIO
Earnings
Guidance Update
Demand Weakening
- For Q3 2025, BIO reported GAAP revenue of $653 million, a 0.5% year-over-year increase, with a GAAP operating margin of 10.0%. Non-GAAP revenue was also $653 million, with a non-GAAP operating margin of 11.8%.
- Currency neutral revenue for Q3 2025 saw a 1.7% year-over-year decline, with both the Life Science Group and Clinical Diagnostics Group experiencing currency neutral revenue declines of 1.5% and 1.8% respectively.
- Net cash from operations for Q3 2025 was $121 million, and free cash flow was $89 million. Cash and short-term investments decreased to $1,419 million as of September 30, 2025, from $1,665 million on December 31, 2024.
- BIO is maintaining its Full-Year 2025 outlook, projecting currency neutral revenue growth of 0.0% to +1.0% and non-GAAP free cash flow between $310 million and $330 million.
Oct 29, 2025, 9:00 PM
Bio-Rad Laboratories Reports Q3 2025 Results and Maintains Full-Year Guidance
BIO
Earnings
Guidance Update
Demand Weakening
- Bio-Rad Laboratories reported Q3 2025 net sales of $653 million, a 0.5% increase on a reported basis but a 1.7% decrease currency-neutral, with non-GAAP diluted earnings per share of $2.26.
- The Life Science segment sales were flat on a reported basis, impacted by continued softness in academic research and biotech funding, while the Clinical Diagnostics segment sales increased 0.6% on a reported basis, despite lower reimbursement rates for diabetes testing in China.
- The company maintained its full-year 2025 outlook, projecting total currency-neutral revenue growth in the range of flat to 1% and a non-GAAP operating margin between 12% and 13%.
- In Q3 2025, Bio-Rad generated $89 million in free cash flow and repurchased 212,578 shares for $53 million. Management expects a modest revenue improvement in life sciences and a return to growth in diagnostics for Q4 2025.
Oct 29, 2025, 9:00 PM
Bio-Rad Reports Q3 2025 Results and Maintains Full-Year Guidance
BIO
Earnings
Guidance Update
Share Buyback
- Bio-Rad reported Q3 2025 net sales of approximately $653 million, a 0.5% increase on a reported basis but a 1.7% decrease currency-neutral, with non-GAAP diluted earnings per share of $2.26 and a non-GAAP operating margin of 11.8%.
- The Life Science segment sales were $262 million, flat on a reported basis, with strong double-digit growth in process chromatography offsetting a 6% year-over-year decrease in core Life Science revenue (excluding process chromatography) due to softness in academic research and biotech funding.
- The Clinical Diagnostics segment sales were $391 million, a 0.6% increase on a reported basis, but a 1.8% decrease currency-neutral, primarily impacted by lower reimbursement rates for diabetes testing in China.
- The company maintained its full-year 2025 outlook for total currency-neutral revenue growth of flat to 1% and non-GAAP operating margin of 12%-13%, anticipating a return to growth in Diagnostics and sequential operating margin improvement of at least 80 basis points in Q4.
- During Q3 2025, Bio-Rad repurchased 212,578 shares for $53 million, with approximately $285 million remaining under the current buyback program.
Oct 29, 2025, 9:00 PM
Bio-Rad Laboratories Reports Q3 2025 Results with Flat Revenue Growth and Maintained Full-Year Guidance
BIO
Earnings
Guidance Update
Demand Weakening
Oct 29, 2025, 9:00 PM
Bio-Rad Reports Third-Quarter 2025 Financial Results
BIO
Earnings
Guidance Update
Demand Weakening
- Bio-Rad Laboratories, Inc. reported Q3 2025 GAAP revenue of $653.0 million, a 0.5% increase compared to Q3 2024, but a 1.7% decrease on a currency-neutral basis.
- The company experienced a GAAP net loss of $(341.9) million, or $(12.70) per diluted share, in Q3 2025, primarily due to a change in the fair market value of its investment in Sartorius AG. In contrast, non-GAAP net income was $60.8 million, or $2.26 per diluted share, for the same period.
- Both the Life Science Group ($261.8 million) and Clinical Diagnostics Group ($391.2 million) saw slight reported sales increases but experienced currency-neutral declines of 1.5% and 1.8% respectively, driven by challenges in academic research, biotech funding, and lower reimbursement rates for diabetes testing in China.
- Bio-Rad is maintaining its full-year 2025 financial outlook, projecting non-GAAP, currency-neutral revenue growth of approximately 0 to 1.0 percent and a non-GAAP operating margin of approximately 12.0 to 13.0 percent.
Oct 29, 2025, 8:16 PM
Bio-Rad Reports Third-Quarter 2025 Financial Results
BIO
Earnings
Guidance Update
Demand Weakening
- Bio-Rad reported Q3 2025 total net sales of $653.0 million, a 0.5% increase compared to Q3 2024, but a 1.7% decrease on a currency-neutral basis. This decline was primarily due to challenges in academic research and biotech funding, and lower reimbursement rates for diabetes testing in China.
- The company reported a GAAP net loss of $(341.9) million, or $(12.70) per diluted share, for Q3 2025, largely due to a change in the fair market value of its investment in Sartorius AG. This contrasts with a net income of $653.2 million, or $23.34 per diluted share, in Q3 2024.
- Non-GAAP net income for Q3 2025 was $60.8 million, or $2.26 per diluted share, an increase from $56.3 million, or $2.02 per diluted share, in Q3 2024.
- Bio-Rad is maintaining its full-year 2025 financial outlook, projecting non-GAAP, currency-neutral revenue growth of approximately 0 to 1.0 percent and a non-GAAP operating margin of approximately 12.0 to 13.0 percent.
Oct 29, 2025, 8:15 PM
Biodesix Expands Partnership with Bio-Rad for Oncology Diagnostic Assays
BIO
New Projects/Investments
Product Launch
- Biodesix, Inc. announced an expanded partnership agreement with Bio-Rad Laboratories to develop, clinically validate, and seek regulatory approval for in vitro diagnostic (IVD) assays focused on oncology applications.
- This collaboration will leverage Bio-Rad’s Droplet Digital™ PCR (ddPCR™) technology on its QX600 platform for highly sensitive detection of multiple genomic markers.
- The initial assays to be validated include Bio-Rad’s ddPLEX ESR1 Mutation Detection Assay, which is critical for HR+/HER2- advanced breast cancer.
- Following regulatory clearance, Biodesix will manufacture and distribute specimen collection kits and offer the ESR1 assay as a test service through its CLIA-CAP laboratory, also pursuing reimbursement from Centers for Medicare & Medicaid Services (CMS).
Oct 22, 2025, 10:17 AM
Bio-Rad Laboratories Inc. Discusses Digital PCR Business and Market Expansion
BIO
Product Launch
New Projects/Investments
Guidance Update
- Bio-Rad's digital PCR (dPCR) business, particularly its Droplet Digital PCR (ddPCR) technology, has evolved significantly since its commercialization in 2010 with the QX100 system, providing absolute quantitation of nucleic acids through droplet-based partitioning.
- The company estimates the digital PCR market at approximately $600 million, with Bio-Rad holding about half of this market. Bio-Rad has expanded its product portfolio with the new QX Continuum and QX700 series platforms, designed to accelerate dPCR adoption through accessible price points and simplified workflows.
- Bio-Rad has raised its 2025 growth guidance to mid-single digits and projects long-term growth rates potentially in the high single digits for this segment. This growth is supported by an industry-leading catalog of over 490,000 validated assays, with an additional 600,000 assays validated for both qPCR and ddPCR to be released in early 2026.
Aug 26, 2025, 6:30 PM
Bio-Rad Laboratories Reports Q4 2024 Results, Announces Stilla Technologies Acquisition, and Provides 2025 Guidance
BIO
Earnings
M&A
Guidance Update
- Bio-Rad Laboratories reported Q4 2024 net sales of $668 million, a 2% reported decline, and a net loss of $716 million or $25.57 diluted loss per share, largely due to a $977 million loss from equity security holdings.
- The company announced a binding offer to acquire Stilla Technologies to enhance its digital PCR portfolio, with the transaction expected to close by the end of Q3 2025.
- A 5% workforce reduction was implemented, anticipated to generate $50-$55 million in savings in 2025 and $60-$65 million in 2026, as part of ongoing cost management.
- For full year 2025, Bio-Rad projects currency-neutral revenue growth between 1.5% and 3.5%, non-GAAP gross margin between 55% and 55.5%, and non-GAAP operating margin between 13% and 13.5%.
- The 2025 outlook factors in headwinds from a China diabetes testing reimbursement reduction (approximately 60 basis points impact on gross and operating margin) and foreign exchange (approximately 40 basis points drag on operating margin).
Feb 13, 2025, 10:00 PM
Quarterly earnings call transcripts for BIO-RAD LABORATORIES.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more